Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Feb 1;167(2):556–569. doi: 10.1084/jem.167.2.556

Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts

PMCID: PMC2188839  PMID: 2964497

Abstract

Detailed information was sought on the capacity of purified Lyt-2+ cells to mediate lethal graft-versus-host disease (GVHD) directed to class I H-2 differences. When B6 Lyt-2+ cells were transferred to irradiated class I-different (B6 x bm 1)F1 mice, three different patterns of lethal GVHD were observed. First, rapid death from hematopoietic failure occurred when Lyt-2+ cells were transferred together with host-type marrow cells; this form of GVHD probably reflected direct destruction of stem cells by Lyt-2+ cytotoxic cells. Second, a pattern of late-onset, chronic GVHD resulting in death only after 4-6 wk occurred when Lyt-2+ cells were supplemented with donor marrow. This syndrome developed in the apparent absence of L3T4+ cells and was observed with either high or low doses of Lyt-2+ cells and with either light or heavy irradiation of the host. Third, an acute form of GVHD resulted when Lyt-2+ cells plus donor marrow cells were supplemented with exogenous help, i.e., by adding small doses of donor L3T4+ cells or injecting the hosts with rIL-2. Although L3T4+ cells potentiated GVHD when injected in small doses, supplementing Lyt-2+ cells with large doses of L3T4+ cells paradoxically led to marked protection; symptoms of GVHD were mild and no deaths occurred.

Full Text

The Full Text of this article is available as a PDF (807.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cobbold S., Martin G., Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation. 1986 Sep;42(3):239–247. doi: 10.1097/00007890-198609000-00003. [DOI] [PubMed] [Google Scholar]
  2. Elkins W. L. Cellular immunology and the pathogenesis of graft versus host reactions. Prog Allergy. 1971;15:78–187. [PubMed] [Google Scholar]
  3. Gale R. P., Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet. 1986 Jun 28;1(8496):1468–1470. doi: 10.1016/s0140-6736(86)91503-5. [DOI] [PubMed] [Google Scholar]
  4. Goronzy J., Weyand C. M., Fathman C. G. Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4. J Exp Med. 1986 Sep 1;164(3):911–925. doi: 10.1084/jem.164.3.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Guy-Grand D., Vassalli P. Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J Clin Invest. 1986 May;77(5):1584–1595. doi: 10.1172/JCI112474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jadus M. R., Peck A. B. Lethal murine graft-versus-host disease in the absence of detectable cytotoxic T lymphocytes. Transplantation. 1983 Sep;36(3):281–289. doi: 10.1097/00007890-198309000-00011. [DOI] [PubMed] [Google Scholar]
  7. Korngold R., Sprent J. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol. 1985 Nov;135(5):3004–3010. [PubMed] [Google Scholar]
  8. Korngold R., Sprent J. T cell subsets and graft-versus-host disease. Transplantation. 1987 Sep;44(3):335–339. doi: 10.1097/00007890-198709000-00002. [DOI] [PubMed] [Google Scholar]
  9. MILLER J. F. Studies on mouse leukaemia. The role of the thymus in leukaemogenesis by cell-free leukaemic filtrates. Br J Cancer. 1960 Mar;14:93–98. doi: 10.1038/bjc.1960.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Malkovský M., Brenner M. K., Hunt R., Rastan S., Doré C., Brown S., North M. E., Asherson G. L., Prentice H. G., Medawar P. B. T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol. 1986 Dec;103(2):476–480. doi: 10.1016/0008-8749(86)90108-5. [DOI] [PubMed] [Google Scholar]
  11. Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J. L., Leblond V., Michallet M., Dreyfus F., Ifrah N. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987 Jul 25;2(8552):175–178. doi: 10.1016/s0140-6736(87)90763-x. [DOI] [PubMed] [Google Scholar]
  12. Martin P. J., Hansen J. A., Storb R., Thomas E. D. Human marrow transplantation: an immunological perspective. Adv Immunol. 1987;40:379–438. doi: 10.1016/s0065-2776(08)60243-6. [DOI] [PubMed] [Google Scholar]
  13. Mizuochi T., Munitz T. I., McCarthy S. A., Andrysiak P. M., Kung J., Gress R. E., Singer A. Differential helper and effector responses of Lyt-2+ T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness. J Immunol. 1986 Nov 1;137(9):2740–2747. [PubMed] [Google Scholar]
  14. O'Reilly R. J. Allogenic bone marrow transplantation: current status and future directions. Blood. 1983 Nov;62(5):941–964. [PubMed] [Google Scholar]
  15. Pollard M., Chang C. F., Srivastava K. K. The role of microflora in development of graft-versus-host disease. Transplant Proc. 1976 Dec;8(4):533–536. [PubMed] [Google Scholar]
  16. Rolink A. G., Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs.-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med. 1983 Aug 1;158(2):546–558. doi: 10.1084/jem.158.2.546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rolink A. G., Pals S. T., Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A. J Exp Med. 1983 Feb 1;157(2):755–771. doi: 10.1084/jem.157.2.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rosenberg A. S., Mizuochi T., Sharrow S. O., Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med. 1987 May 1;165(5):1296–1315. doi: 10.1084/jem.165.5.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sprent J. Fate of H2-activated T lymphocytes in syngeneic hosts. I. Fate in lymphoid tissues and intestines traced with 3H-thymidine, 125I-deoxyuridine and 51chromium. Cell Immunol. 1976 Feb;21(2):278–302. doi: 10.1016/0008-8749(76)90057-5. [DOI] [PubMed] [Google Scholar]
  20. Sprent J., Schaefer M., Lo D., Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med. 1986 Apr 1;163(4):998–1011. doi: 10.1084/jem.163.4.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sprent J., Schaefer M. Properties of purified T cell subsets. I. In vitro responses to class I vs. class II H-2 alloantigens. J Exp Med. 1985 Dec 1;162(6):2068–2088. doi: 10.1084/jem.162.6.2068. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES